



Published in final edited form as:

Cancer Prev Res (Phila). 2011 November ; 4(11): 1912–1919. doi:10.1158/1940-6207.CAPR-11-0002.

Mitochondrial DNA Copy Number and Pancreatic Cancer in the Alpha-Tocopherol Beta-Carotene Cancer Prevention (ATBC) Study

Shannon M. Lynch^{1,2}, Stephanie J. Weinstein¹, Jarmo Virtamo³, Qing Lan⁴, Chin-San Lui⁵, Wen-Ling Cheng^{5,6}, Nathaniel Rothman⁴, Demetrius Albanes¹, and Rachael Z. Stolzenberg-Solomon¹

¹Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD ²Center for Clinical Epidemiology and Biostatistics, Center for Genetics and Complex Traits, University of Pennsylvania, Philadelphia, PA ³Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland ⁴Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD ⁵Department of Neurology and Vascular and Genomic Research Center, Changhua Christian Hospital, Changhua 500, Taiwan ⁶Graduate Institute of Integrated Medicine, China Medical University, Taichung 404, Taiwan

Abstract

Background—Diabetes, obesity, and cigarette smoke, consistent risk factors for pancreatic cancer, are sources of oxidative stress in humans that could cause mitochondrial DNA (mtDNA) damage and increase mtDNA copy number.

Methods—To test whether higher mtDNA copy number is associated with increased incident pancreatic cancer, we conducted a nested case-control study in the Alpha-Tocopherol Beta Carotene Cancer Prevention (ATBC) Study cohort of male smokers, aged 50-69 years at baseline. Between 1992 and 2004, 203 incident cases of pancreatic adenocarcinoma occurred (follow-up: 12 years) among participants with whole blood samples used for mtDNA extraction. For these cases and 656 controls, we calculated odds ratios (OR) and 95% confidence intervals using unconditional logistic regression, adjusting for age, smoking, and diabetes history. All statistical tests were two-sided.

Results—Higher mtDNA copy number was significantly associated with increased pancreatic cancer risk (highest vs. lowest mtDNA copy number quintile, OR=1.64, 95% CI=1.01-2.67, continuous OR=1.14, 95% CI 1.06-1.23), particularly for cases diagnosed during the first 7 years of follow-up (OR=2.14, 95% CI=1.16-3.96, p-trend=0.01, continuous OR=1.21, 95% CI 1.10-1.33), but not for cases occurring during follow-up of 7 years or greater (OR= 1.14, 95% CI=0.53-2.45, continuous OR=1.05, 95% CI 0.93-1.18).

Conclusion—Our results support the hypothesis that mtDNA copy number is associated with pancreatic cancer and could possibly serve as a biomarker for pancreatic cancer development.

Introduction

Pancreatic adenocarcinoma is the fourth leading cause of cancer mortality in the United States (1) and the fifth worldwide (2). There is no effective screening method to detect early pancreatic cancer, which accounts for its poor five-year survival rate of less than 5% (3). Although not well-understood, mitochondria function and mitochondrial DNA (mtDNA) damage has been hypothesized to potentiate carcinogenesis (4). Mitochondria are both the primary target and the key intracellular source of reactive oxygen species (ROS) and oxidative stress (6). mtDNA is particularly susceptible to damage from ROS because they lack protective histones, have diminished DNA repair capacity, and are in close proximity to the electron transport chain, which releases ROS (7). Studies have suggested that mitochondria increase the number of copies of mtDNA to compensate for mtDNA damage and mitochondrial dysfunction(8). Each cell has thousands of mitochondrion, and each mitochondrion within normal cells have between 2 and 10 copies of their genomes, depending on the cell type (5). Previous studies investigating mtDNA copy number in leukocytes and disease outcomes have found an average mtDNA copy number in controls ranging from 96-107.3 (9,10) and a log-transformed average mtDNA copy number for subjects over 50 around 3.0 (11) . Some of these studies included women only, women and men, and children; differences in mtDNA copy number by age or sex are not well-understood.

Diabetes, obesity, and cigarette smoke, consistent risk factors for pancreatic cancer are sources of oxidative stress in humans (12-15). Oxidative stress occurs when there is an imbalance between oxidants and antioxidants, and this imbalance could cause mitochondrial damage and affect mtDNA copy number. For instance, a component of cigarette smoke, polycyclic aromatic hydrocarbons (PAHs), has a 40–90-fold greater affinity for mtDNA compared to nuclear DNA (16), and to compensate for damage from PAHs, mtDNA content increases (8). In a recent study, hyperglycemia was associated with increasing mtDNA content, and the mtDNA copy number was also correlated with plasma concentrations of thiobarbituric acid reactive substances, a biomarker of glucose metabolism (17). Because antioxidants found in food, vitamins and minerals (e.g. alpha-tocopherol, beta-carotene) help to neutralize ROS released during oxidative processes, we hypothesize that antioxidants also may be associated with reduced mtDNA copy number (18).

While studies investigating mtDNA genomic mutations have been conducted in pancreatic cancer (19,20), no study has evaluated the role of mtDNA copy number and pancreatic cancer risk. Therefore, to better elucidate the relationship between mtDNA copy number and pancreatic cancer, we conducted a nested case-control study within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study cohort of male smokers. The ATBC Study is uniquely positioned to investigate the relationship between mtDNA copy number and pancreatic cancer risk because of the population's exposure to oxidative stress due to smoking, their exposure to the beta-carotene and alpha-tocopherol study intervention, and the collection of biomarkers (beta-carotene, alpha-tocopherol, and retinol measured at baseline and after the study intervention), all of which can potentially modify mtDNA copy number.

Methods

Study Population

The ATBC Study was a double-blind, placebo-controlled, 2×2 factorial-design primary prevention trial that tested whether alpha-tocopherol or beta-carotene supplementation reduced cancer incidence in Finnish male smokers (21). The study rationale, design, and methods have been described previously (21). Between 1985 and 1988, 29,133 eligible men

aged 50–69 years in southwestern Finland who smoked at least 5 cigarettes per day were randomized to receive active supplements or placebo (21). Men were excluded from the study if they had a history of malignancy other than nonmelanoma skin cancer or carcinoma in situ, severe angina on exertion, chronic renal insufficiency, liver cirrhosis, chronic alcoholism, or another medical condition that might limit long-term participation; if they were receiving anticoagulant therapy; or if they were using supplements containing vitamin E (>20 mg/day), vitamin A (>20,000 IU/day), or beta-carotene (>6 mg/day). All study participants provided written informed consent prior to randomization, and the study protocol was approved by the institutional review boards of both the National Public Health Institute in Finland and the National Cancer Institute in the United States.

During a pre-randomization baseline visit, participants completed questionnaires on general background characteristics, including medical, smoking, dietary, and physical activity histories (21). Trained study staff measured height, weight, and blood pressure at baseline using standard methods. Body mass index (BMI; weight (kg)/height(m)²) was calculated from measured weight and height. Diet was assessed with a validated self-administered dietary history questionnaire(21). Occupational activity was assessed by asking how much exercise and physical burden had been undertaken at work during the past year; responses could range from not working or sedentary to heavy physical work. Leisure-time activity was assessed by asking about the average level of activity engaged in during the past year; responses ranged from sedentary (reading, watching television) to moderate (walking, fishing, hunting, gardening regularly) to heavy or “exercising to keep fit” (running, jogging, or skiing regularly).

Serum samples were collected at two time points from study participants: 1) after an overnight fast, during the prerandomization visit on the entire cohort (n=29,111); and 2) 3 years after randomization at a follow-up visit on 26,546 study participants(post-intervention). Whole blood samples were collected at one time point towards the end of the study between 1992 and 1993. The median time between baseline and the post-intervention serum blood collection was 3.02 years; the median time between post-intervention serum blood collection and whole blood collection was 2.65 years. All samples were stored at –70 degrees *Celsius*.

Case Ascertainment and Control Selection

Cancer cases within the ATBC cohort were identified by linking the cohort to the Finnish Cancer Registry. The Finnish Cancer Registry provides nearly 100% case ascertainment in Finland and accurately reports 89% of primary pancreatic cancer cases (The ATBC Study, 1994)(21,22). We included incident primary malignant neoplasm of the exocrine pancreas (ICD9-157) and excluded endocrine tumors (ICD9-157.4) for this analysis. The pancreatic cancer diagnosis was confirmed through central review of all relevant hospital records for cases diagnosed from baseline through April 1999, whereas cases diagnosed after April 1999 were based solely on Finnish Cancer Registry data. Between 1992 and 2004 (follow-up to 12 years, median 6.3 years), 203 incident pancreatic cancer cases were identified among the subjects that had whole blood samples collected and from which DNA could be extracted.

Controls were selected from the ATBC Study and included participants who had whole blood samples for DNA extraction, and were alive and free of cancer (except nonmelanoma skin cancer) at the time the case was diagnosed. Controls (n=406) were matched to each pancreatic cancer case by date of birth (± 5 years) in a 2:1 ratio of controls to cases. We also included additional controls from other ATBC nested case-control studies (n=250) with mtDNA data that were measured concurrently with our study measurements (23, 24). There were no statistically significant differences between the two control groups for the

characteristics listed in Tables 1 and 2 (data not shown). Therefore, to increase study power, we used the pooled control set for this analysis (n=656).

Biomarkers

Serum alpha-tocopherol and beta-carotene were measured within 2 years of serum collection by high-performance liquid chromatography as described in Milne and Botnen (25). DNA was extracted from peripheral white blood cells of the whole blood sample using the phenol-chloroform method and used to measure mtDNA copy number. Fluorescence-based quantitative polymerase chain reaction (PCR) was used to determine the total mtDNA copy number by using the estimation of threshold cycle number of ND1, a mitochondrial gene, and that of the beta-globin gene, *HBB*, a nuclear gene (18). mtDNA copy number is reported as the number of mtDNA copies per cell.

Case and control specimens were handled in the same standard manner, and the laboratory was blinded to case-control status. Case and control samples were analyzed consecutively within batches, and blinded replicate “phantom” samples from three donor samples were placed within the batches, comprising 10 percent of each batch (26). Across all batches (pancreatic and lung cancers and lymphoma), the interbatch coefficient of variance (CV%) was 11.2% and the intrabatch CV% was 6.75%.

Statistical Analysis

A total of 203 pancreatic cancer cases and 656 controls were used for this analysis. We compared distributions of selected case and control characteristics using the Wilcoxon rank-sum test for continuous variables and the chi-squared test for categorical variables (Table 1). Among control participants, generalized linear models were used to calculate mean values for continuous variables, and frequencies were used to calculate proportions (percentages) for the categorical variables to describe selected control characteristics across mtDNA copy number quintiles (Table 2). We also evaluated the correlation between continuous variables using Spearman correlation methods and results were similar to those reported in Table 2. Variables examined in the analyses and as potential confounders in the risk models were based on previous findings from the ATBC Study cohort or were associated with pancreatic cancer in the literature. Variables examined as potential confounders include those listed in Table 1, as well as self-reported history of chronic bronchial asthma; fruit and vegetable intake; and measured systolic and diastolic blood pressure. Dietary nutrients and foods highly correlated with energy intake were adjusted for energy using the residual method described by Willett and Stampfer (27).

Matching between cases and controls was not retained for the analyses because we used a pooled control set. Unconditional logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (95% CI) for pancreatic cancer, with men in the lowest mtDNA copy number quintile serving as the reference category. mtDNA copy number was analyzed as both categorical and continuous variables. MtDNA was categorized into quintiles based on the distribution of controls. A score variable for mtDNA copy number based on the median values of each category was created to test trend. Continuous variables are presented based on a 21 unit change, which corresponds to the average unit change within quintiles 2-4 for the whole case-control set.

Multivariable models were developed using forward and backward regression by individually entering or subtracting potentially confounding variables into the model. mtDNA copy number was the exposure of interest and was therefore forced into all the models. Variables remained in the model if they were associated with both the disease and mtDNA copy number, had a P value of 0.10 or less in the full model, changed the risk

estimate by more than 10% or were putative risk factors for pancreatic cancer. The final multivariable models included putative risk factors for pancreatic cancer, namely age (continuous), smoking history (duration or years smoked and intensity or number of cigarettes per day-continuous) and history of diabetes (yes/no). Quartiles of mtDNA copy number were used in evaluating interactions in order to have adequate number of subjects in each cell. Effect modification of the mtDNA association by age, intervention, saturated fat intake, history of diabetes, body mass index, smoking (cigarettes smoked per day and years smoked) and baseline and post-intervention serum alpha-tocopherol and beta-carotene, was evaluated in stratified analysis and by taking the cross-product terms of the mtDNA score variable, and the dichotomized effect modifier (with median split cutoffs) in multivariable models. We also stratified our analysis by follow-up time from whole blood collection to case diagnosis to assess the potential for reverse causation. We conducted sensitivity analyses, stratifying by follow-up time at 4, 5, 6, 7, 8, 9, and 10 years in order to determine if risk changed during follow-up and found that 7 years best represented where the risk changed during follow-up. All statistical analyses were performed using SAS software (SAS Institute Inc., Cary, North Carolina). The P values for all statistical tests were 2-sided, and an alpha level of 0.05 was used to determine statistical significance.

Results

The median time from whole blood collection and pancreatic cancer diagnosis was 6.3 years. MtDNA copy number was significantly different between cases and controls ($p=0.04$), with cases having a higher median mtDNA copy number (130.4; range 100-161.8 vs 122.2; range 100-147.1) (Table 1). Cases and controls did not significantly differ with respect to most characteristics; cases tended to have a greater history of diabetes, smoked for a longer time period, and consume more saturated fat and less carbohydrate (Table 1). The mean mtDNA copy number was 137.2 copies per cell for cases (standard deviation, 50; range, 60.5-362.9) and 126.9 copies per cell for controls (standard deviation, 37.3; range, 44.1-362.9).

Table 2 shows the means and percentages of selected baseline characteristics among the controls according to quintile of mtDNA copy number. No clear, consistent trend existed for the selected baseline characteristics and mtDNA copy number. Men in the lowest quintile of mtDNA copy number tended to have smoked the most cigarettes for a greater number of years, and had the highest number of pack-years (P -trend=0.05).

MtDNA copy number was significantly associated with pancreatic cancer risk (highest mtDNA copy number quintile compared to lowest quintile, OR=1.64, 95% CI=1.01-2.67, p -trend=0.04) and in continuous models (OR=1.14, 95% CI=1.06-1.23) (Table 3). We also performed a dichotomous analysis by splitting mtDNA copy number at the median (OR=1.25, 95% CI=1.01-1.79). Similar associations were observed when comparing quartiles of mtDNA copy number (adjusted OR for 4th quartile versus 1st quartile=1.21, 95% CI=1.01-1.34; test for trend p -value=0.09) and when we restricted our analysis to the matched case-control sets and used conditional logistic regression to estimate risk (highest compared to lowest quintile, OR=1.23, 95% CI=0.62-2.43, continuous OR= 1.13, 95% CI=1.02-1.26). Patterns were similar when restricting the analysis to pancreas and lung controls only (Adjusted ORs for the 1st-5th quintiles in order=1.00, 0.76, 0.54, 0.94, 1.15; continuous OR=1.10, 95% CI=1.01-1.19) and to pancreas and lymphoma controls only (Adjusted ORs for the 1st-5th quintile in order=1.00, 0.82, 0.63, 1.08, 1.43; continuous OR=1.12, 95% CI=1.04-1.22). The association between mtDNA copy number and pancreatic cancer was strongest in cases diagnosed during the first 7 years of follow-up (highest mtDNA copy number quintile OR= 2.14, 95% CI=1.16-3.96, p -trend=0.01, continuous OR=1.21, 95% CI 1.10-1.34, $p=0.02$), but not in cases occurring during follow-up greater

than 7 years (highest mtDNA copy number quintile OR= 1.14, 95% CI=0.53-2.45, continuous OR=1.05, 95% CI 0.93-1.18).

Study intervention group did not significantly modify the association between mtDNA copy number and pancreatic cancer risk, although in adjusted models, positive associations appeared strongest among those randomized to the alpha-tocopherol (AT) supplementation group (continuous OR=1.30, 95% CI=1.09-1.57, p-trend=0.004; data not shown). However, there was no significant interaction by baseline serum alpha-tocopherol and serum alpha-tocopherol measured after the study intervention. The association between mtDNA copy number and pancreatic cancer was not modified by age, smoking habits, body mass index, physical activity, saturated fat, total energy, folate or carbohydrate intake, other dietary factors (antioxidants, fruit/vegetable intake), history of diabetes or gallstones, and physical activity levels (all P-values >0.05).

Discussion

To our knowledge, this is the first study to evaluate and show a statistically significant positive association between higher mtDNA copy number and pancreatic cancer risk. The association was more pronounced among cases that occurred during the first 7 years of follow-up. In our study, the mean mtDNA copy number for controls was 126.9, and the log-transformed mean was around 4.8. Antioxidants and other dietary factors believed to lower mtDNA copy number did not appear to affect copy number in this analysis. Our mtDNA copy number measures may be higher than previously reported studies because our participants are current smokers and smoking increases oxidative stress, which is known to increase mtDNA copy number (8).

Most studies investigating the association between mtDNA copy number and cancer are case-control (28,29,30,31, 32) or nested case-control (23,24) designs, comparing cancer cases to normal controls or normal tissue to tumors at different stages. Inconsistent associations have been observed between mtDNA copy number measured in peripheral blood or tumor tissue for certain cancers including renal cell carcinoma (33,28), non-hodgkin lymphoma (23), breast (34,29), head and neck (35,36), endometrium (30), stomach (31) lung (32,24) and ovarian (37) cancer. Specifically, both positive and inverse associations have been observed across cancer sites and in some instances, within cancer sites (i.e. ovary, head and neck cancers), regardless if mtDNA copy number was measured in blood or tissue. These inconsistencies may reflect true differences in mtDNA levels within or across the tumor types. Alternatively, the inconsistencies might be due to differences in study designs (i.e. case-control vs. prospective nested case-control) or laboratory methods used to quantify mtDNA (11). For example, mtDNA copy number was higher in early-stage ovarian tumors, whereas late stage tumors had lower mtDNA copy number (37). A recent biological study on gastric cancer tissue suggested that mitochondrial DNA instability may play a role in early events leading to cancer progression (37). These findings suggest that changes in mtDNA content might be a genetic event in the progression of carcinogenesis (37,38). Because we are using a nested case-control study approach, we were able to assess the possibility of reverse causation and show that mtDNA copy number was elevated prior to diagnosis, unlike case-control studies that cannot ascertain temporal exposure in relation to disease. As the associations we observe are more pronounced among cases occurring earlier during follow-up, our results suggest increased levels of mtDNA copy number may be an early biomarker of sub-clinical pancreatic cancer in certain populations.

The strength of our study is its prospective nature, with blood samples and other risk factor data collected prior to cancer diagnosis. The cases and controls were both obtained from the

larger cohort study; therefore, our study has internal validity, and no survival bias of cases or selection bias of controls. Our findings in male smokers, however, may not be generalizable to populations that include women and nonsmokers. In particular, the association between mtDNA copy number and pancreatic cancer may be different in populations not exposed to factors that induce oxidative stress, such as cigarette smoke (12,13). Residual confounding by cigarette smoking is possible but unlikely because all subjects were current smokers at baseline, self-reported current smoking is highly accurate in adults (39), and the smoking exposures were not effect modifiers in any association. In addition, the association was the same when we limited the analysis to those who smoked 20 cigarettes per day, which is equivalent to 1 pack.

Our study also has limitations. We did not have repeated measures of mtDNA copy number and a single measurement may not reflect mtDNA copy number over a lifetime. Repeated measures may help clarify the temporal relationship between mtDNA copy number and pancreatic cancer development. In addition, the number of cases in our study is relatively small, particularly to evaluate interactions.

In conclusion, we found a significant association between higher mtDNA copy number and increased pancreatic cancer risk, particularly for cases diagnosed within 7 years of whole blood collection. Further research is needed to evaluate our findings in other populations and to explore the potential use of mtDNA copy number as an early detection biomarker.

Acknowledgments

We would like to thank Cari L. Meinhold for her assistance.

Funding The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study was supported in part by US Public Health Service contracts N01-CN-45165, N01-RC-45035, and N01-RC-37004 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services.

References

1. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. *Cancer*. 2004; 101:3–27. [PubMed: 15221985]
2. Johns Hopkins University. The Sol Goldman Pancreatic Cancer Research Center. Johns Hopkins and You. Participating in Research Specific to African Americans. Johns Hopkins University Press; Baltimore, MD: 2003. <http://pathology.jhu.edu/pancreas/PartAfAm.php>
3. Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975–2002, featuring population based trends in cancer treatment. *J Natl Cancer Inst*. 2005; 97(19): 1407–1427. [PubMed: 16204691]
4. Wallace DC. Mitochondria and cancer: Warburg addressed. *Cold Spring Harb Symp Quant Biol*. 2005; 70:363–374. [PubMed: 16869773]
5. Penta JS, Johnson FM, Wachsmann JT, et al. Mitochondrial DNA in human malignancy. *Mutat Res*. 2001; 488:119–133. [PubMed: 11344040]
6. Chan DC. Mitochondria: dynamic organelles in disease, aging, and development. *Cell*. 2006; 125:1241–1252. [PubMed: 16814712]
7. Clayton DA. Transcription of the mammalian mitochondrial genome. *Annu Rev Biochem*. 1984; 53:573–594. [PubMed: 6383200]
8. Lee HC, Lu CY, Fahn HJ, et al. Aging- and smoking-associated alteration in the relative content of mitochondrial DNA in human lung. *FEBS Lett*. 1998; 441:292–6. [PubMed: 9883902]
9. Kim MY, Lee JW, Kang HC, Kim E, Lee DC. Leukocyte mitochondrial DNA (mtDNA) content is associated with depression in old women. *Arch Gerontol Geriatr*. Dec 13.2010
10. Milazzo, Laura; Menzaghi, Barbara; Caramma, Ilaria; Nasi, Milena; Sangaletti, Ornella; Cesari, Miriam; Poma, Barbara Zanone; Cossarizza, Andrea; Antinori, Spinello; Galli, Massimo. *AIDS*

- Research and Human Retroviruses. November; 2010 26(11):1207–1214. doi:10.1089/aid.2010.0024. [PubMed: 20977356]
11. Liu CS, Cheng WL, Lee CF, Ma YS, Lin CY, Huang CC, Wei YH. Alteration in the copy number of mitochondrial DNA in leukocytes of patients with mitochondrial encephalomyopathies. *Acta Neurol Scand*. May; 2006 113(5):334–41. [PubMed: 16629770]
 12. Bruno RS, Ramakrishnan R, Montine TJ, et al. a-Tocopherol disappearance is faster in cigarette smokers and is inversely related to their ascorbic acid status. *Am J Clin Nutr*. 2005; 81:95–103. [PubMed: 15640466]
 13. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. *Arterioscler Thromb Vasc Biol*. 2004; 24:816–23. [PubMed: 14976002]
 14. Lynch SM, Vrieling A, Lubin JH, et al. Cigarette Smoking and Pancreatic Cancer: A Pooled Analysis from the Pancreatic Cancer Cohort Consortium (PanScan). *Am J Epidemiol*. 2009; 170(4):403–13. [PubMed: 19561064]
 15. Stolzenberg-Solomon RZ, Graubard BI, Chari S, et al. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. *JAMA*. 2005; 294(22):2872–2878. [PubMed: 16352795]
 16. Allen JA, Coombs MM. Covalent binding of polycyclic aromatic compounds to mitochondrial and nuclear DNA. *Nature*. 1980; 287:244–245. [PubMed: 7432460]
 17. Weng SW, Lin TK, Liou CW, et al. Peripheral blood mitochondrial DNA content and dysregulation of glucose metabolism. *Diabetes Res Clin Pract*. 2009; 83(1):94–9. [PubMed: 19019479]
 18. Liu CS, Tsai CS, Kuo CL, et al. Oxidative Stress-related Alteration of the Copy Number of Mitochondrial DNA in Human Leukocytes. *Free Radical Research*. 2003; 37:1307–1317. [PubMed: 14753755]
 19. Wang L, Bamlet WR, de Andrade M, et al. Mitochondrial genetic polymorphisms and pancreatic cancer risk. *Cancer Epidemiol Biomarkers Prev*. 2007; 16(7):1455–9. [PubMed: 17627010]
 20. Halfdanarson TR, Wan L, Bamlet WR, et al. Mitochondrial Genetic Polymorphisms Do Not Predict Survival in Patients with Pancreatic Cancer. *Cancer Epidemiol Biomarkers Prev*. 2008; 17(9):2512–2513. [PubMed: 18768524]
 21. The ATBC Cancer Prevention Study Group. The Alpha-Tocopherol, Beta-Carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. *Ann Epidemiol*. 1994; 4:1–10. [PubMed: 8205268]
 22. Korhonen P, Malila N, Pukkala E, Teppo L, Albanes D, Virtamo J. The Finnish Cancer Registry as follow-up source of a large trial cohort--accuracy and delay. *Acta Oncol*. 2002; 41:381–8. [PubMed: 12234031]
 23. Lan Q, Lim U, Liu CS, et al. A prospective study of mitochondrial DNA copy number and risk of non-Hodgkin lymphoma. *Blood*. 2008; 112:4247–4249. [PubMed: 18711000]
 24. Hosgood HD, Liu CS, Rothman N, Weinstein SJ, et al. Mitochondrial DNA copy number and lung cancer risk in a prospective cohort study. *Carcinogenesis*. 2010; 31(5):847–9. [PubMed: 20176654]
 25. Milne DB, Botnen J. Retinol, alpha-tocopherol, lycopene, and alpha- and beta-carotene simultaneously determined in plasma by isocratic liquid chromatography. *Clin Chem*. 1986; 32:874–876. [PubMed: 3084131]
 26. Fears TR, Ziegler RG, Donaldson JL, et al. Reproducibility studies and interlaboratory concordance for androgen assays in female plasma. *Cancer Epidemiol Biomarkers Prev*. 2000; 9(4):403–412. [PubMed: 10794485]
 27. Willett W, Stampfer MJ. Total energy intake: implications for epidemiologic analyses. *Am J Epidemiol*. 1986; 124(1):17–27. [PubMed: 3521261]
 28. Xing J, Chen M, Wood CG, et al. Mitochondrial DNA content: its genetic heritability and association with renal cell carcinoma. *J Natl Cancer Inst*. 2008; 100(15):1104–12. [PubMed: 18664653]
 29. Yu M, Zhou Y, Shi Y, et al. Reduced mitochondrial DNA copy number is correlated with tumor progression & prognosis in Chinese breast cancer patients. *IUBMB Life*. 2007; 59(7):450–457. [PubMed: 17654121]

30. Wang Y, Liu VW, Xue WC, et al. The increase of mitochondrial DNA content in endometrial adenocarcinoma cells: a quantitative study using laser-captured microdissected tissues. *Gynecol Oncol.* 2005; 98:104–110.30. [PubMed: 15921730]
31. Wu CW, Yin PH, Hung WY, et al. Mitochondrial DNA mutations and mitochondrial DNA depletion in gastric cancer. *Genes Chromosomes Cancer.* 2005; 44:19–28. [PubMed: 15892105]
32. Bonner MR, Shen M, Liu CS, et al. Mitochondrial DNA content and lung cancer risk in XuanWei, China. *Lung Cancer.* 2008; 63(3):331–4. [PubMed: 18691788]
33. Meierhofer D, Mayr JA, Foetschl U, et al. Decrease of mitochondrial DNA content and energy metabolism in renal cell carcinoma. *Carcinogenesis.* 2004; 25:1005–1010. [PubMed: 14764459]
34. Radpour R, Fan AX, Kohler C, et al. Current Understanding of Mitochondrial DNA in Breast Cancer. *Breast J.* 2009; 15(5):505–9. [PubMed: 19624415]
35. Jiang WW, Rosenbaum E, Mambo E, et al. Decreased mitochondrial DNA content in posttreatment salivary rinses from head and neck cancer patients. *Clin Cancer Res.* 2006; 12:1564–1569. [PubMed: 16533782]
36. Kim MM, Clinger JD, Masayeva BG, et al. Mitochondrial DNA quantity increases with histopathologic grade in premalignant and malignant head and neck lesions. *Clin Cancer Res.* 2004; 10:8512–8515. [PubMed: 15623632]
37. Wang Y, Liu VW, Xue WC, et al. Association of decreased mitochondrial DNA content with ovarian cancer progression. *Br J Cancer.* 2006; 95(8):1087–91. [PubMed: 17047655]
38. Jeong CW, Lee JH, Sohn SS, et al. Mitochondrial Microsatellite Instability in Gastric Cancer and Gastric Epithelial Dysplasia as a Precancerous Lesion. *Cancer Epidemiology.* 2010; 34:323–327. [PubMed: 20409774]
39. Slattery ML, Hunt SC, French TK, et al. Validity of cigarette smoking habits in three epidemiologic studies in Utah. *Prev Med.* 1989; 18:11–19. [PubMed: 2785267]

Table 1

Baseline Characteristics of Case & Control Subjects, Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study.

Characteristics	Cases Median	(n=203) IQR	Controls Median	(n=656) IQR	p-value [‡]
MtDNA copy number, median [†]	130.4	100.0-161.8	122.2	100.0-147.1	0.04
Age, years	58	54-61	58	54-62	0.78
Height, cm	174	170-179	173	169-178	0.14
Body mass index (units)	26.2	23.9-28.2	25.7	23.7-28.5	0.57
Smoking History					
Total cigarettes smoked/day	20	15-25	18	15-25	0.88
Years of smoking	37	31-42	36	31-42	0.08
Pack-years of smoking	35	24-45	34	23-44	0.13
Medical History (%)	7.4				
Diabetes mellitus	2		4.4		0.09
Pancreatitis	3.9		0.8		0.14
Gallstones	18.2		5.6		0.34
Peptic Ulcers	75.4		17.1		0.70
Primary school education or less(%)	42.4		77.9		0.45
Living in city (%)	7.4		47.7		0.18
Daily dietary intake [§]					
Energy, kcal	2688	2236-3170	2585	2164-3136	0.25
Total fat, g [§]	123	114.3-133	122	113-132	0.28
Saturated fat, g [§]	53	45-64	52	43-60	0.07
Carbohydrate, g [§]	264	236-288	269	246-289	0.10
Protein, g [§]	94	87-100	94.1	86-101	0.79
Folate, ug [§]	337	275-402	328	269-392	0.37
Alcohol, g	9.2	2.42-26.8	10.7	2.5-24.0	0.96
Physical activity (%)					
Occupational activity					0.91
Sedentary	15.3		13.4		
Moderate	33		32.9		

Characteristics	Cases Median	(n=203) IQR	Controls Median	(n=656) IQR	p-value ‡
Heavy	7.9		8.7		
Not working	43.8		45		
Leisure activity					0.49
Sedentary	40.1		36		
Light or moderate	53		55.3		
Exercising to keep fit	6.9		8.7		
Serum Levels-Baseline§					
Baseline AT, ug/L	11.9	9.7-13.8	11.8	10.0-13.6	0.65
Baseline BC, ug/L	162	110.0-270	190	122.0-281	0.17
Retinol, ug/L	574	479.0-664	574	496.0-668	0.53
Serum-post-intervention§					
AT, ug/L¶	17.2	14.9-20.8	17.6	15.2-20.1	0.98
BC, ug/L¶	3016	1386-4817	3117	2124-3907	0.87
Retinol, ug/L	596	494-674	584	503-683	0.72
Randomization Group(%)					
Alpha-Tocopherol (AT)	24.6		25.6		0.87
Beta-Carotene (BC)	21.7		24.9		
AT and BC	26.1		24.2		
Placebo	27.6		25.3		

‡ Units of measurement=number of copies of mitochondrial DNA per cell

‡ P values for categorical variables were based on the chi-squared test or Fisher's exact test; P values for continuous variables were based on Wilcoxon's rank-sum test.

§ Adjusted by total energy intake. Number of controls=609.

¶ Number of controls=642; Post intervention serum measures limited to subjects in the intervention arm only

Table 2

Select Characteristics of Control Subjects by mtDNA Copy Number (Quintiles) †

Characteristic	mtDNA Copy Number Quintiles				
	Q1 ≤94.6	Q2 >94.6-≤113.3	Q3 >113.3-≤132.8	Q4 >132.8-≤158.0	Q5 >158.0
mtDNA Copy Number [‡] , §	83.2	104.2	123.6	144.5	186.2
Age, years §	58	58	58	58	58
Height, cm §	174	173	174	173	173
BMI ^c (units)	26.4	26.5	26.1	26.4	26
Smoking history					
Cigarettes smoked per day	20.5	18.8	19.3	18.8	18
Years of smoking	36.4	37	35.9	35.5	35.1
Pack-years of smoking	38.2	34.9	35	34.1	32.4
Medical history, %					
Diabetes mellitus	3.8	6.8	5.6	3.1	2.5
Pancreatitis	2.3	0	0	0.8	0.9
Gallstones	10.5	7.5	2.8	1.5	5.9
Peptic					
Ulcers	20.3	15	16.2	15.4	18.6
Primary education or less, %	79	75.9	81	75.4	78
Living in city, %	45.9	46.6	51.4	40.8	54.2
Daily dietary intake §					
Energy, kcal	2610	2713	2659	2662	2700
Total fat, g	124	121	121	122	125
Saturated fat, g	53	51	52	53	54
Carbohydrate, g	268	266	272	269	270
Protein, g	94	95	95	96	94
Folate ^d , ug	333	348	342	336	344
Alcohol, g	15.8	20.2	16.5	16.3	13.8
Physical Activity, %					

Characteristic	MitDNA Copy Number Quintiles				
	Q1 ≤94.6	Q2 >94.6-≤113.3	Q3 >113.3-≤132.8	Q4 >132.8-≤158.0	Q5 >158.0
Occupational activity					
Sedentary	10.5	16.5	9.2	18.5	12.7
Moderate	36.8	35.3	30.3	28.5	33.9
Heavy	7.5	7.2	6.6	5.6	6.1
Not working	45.9	41.4	51.4	43.1	42.4
Leisure activity					
Sedentary	37.6	39.1	27.5	41.5	34.8
Light or moderate	53.4	54.9	60.6	51.5	55.9
Exercising to keep fit	9	6	12	6.9	9.3
Serum levels-Baseline §					
AT, ug/L	12.1	12.4	12.1	12.2	11.9
BC, ug/L	230	214	228	233	230
Retinol, ug/L	565	602	583	607	588
Serum-post-intervention **, §					
AT, ug/L	18.1	17.7	17.6	18.4	18.2
BC, ug/L	2953	3167	3615	2961	3043
Retinol, ug/L	588	611	585	630	597
Randomization Group					
Alpha-Tocopherol (AT)	33.8	19.6	30.3	23.9	19.5
Beta-Carotene (BC)	21.1	30.1	23.3	24.6	25.4
AT and BC	21.8	23.3	23.2	23.9	29.7
Placebo	23.3	27.1	23.2	27.7	25.4

† Based on Total number of controls n=656

‡ Units of measurement=number of copies of mitochondrial DNA per cell

§ Mean values unless otherwise noted

// Adjusted by total energy intake. Number of controls=609.

** Number of controls=642; Post intervention serum measures limited to subjects in the intervention arm only

Table 3
Crude and Adjusted Odds Ratios and 95% Confidence Intervals for mtDNA Copy Number and Pancreatic Cancer Risk

	mtDNA Copy Number					P-trend [†]	Continuous OR [‡]
	Q1 ≤94.6	Q2 >94.6-≤113.3	Q3 >113.3-≤132.8	Q4 >132.8-≤158.0	Q5 >158.0		
n (cases/controls)	38/133	39/133	30/142	43/130	53/118		203/656
Crude	1.00 (ref)	1.03 (0.62-1.71)	0.74 (0.43-1.26)	1.16 (0.70-1.91)	1.57 (0.97-2.55)	0.06	1.13 (1.05-1.22)
Adjusted [§]	1.00 (ref)	1.04 (0.63-1.74)	0.75 (0.44-1.28)	1.22 (0.74-2.02)	1.64 (1.01-2.67)	0.04	1.14 (1.06-1.23)
Cases diagnosed <7 years after whole blood collection							
n (cases/controls)	38/118	23/130	13/142	21/133	23/133		118/656
Crude	1.00 (ref)	0.91 (0.48-1.75)	0.53 (0.26-1.10)	1.02 (0.55-1.91)	1.86 (1.05-3.31)	0.05	1.13 (1.05-1.22)
Adjusted [§]	1.00 (ref)	0.78 (0.38-1.59)	0.60 (0.28-1.27)	1.16 (0.59-2.27)	2.14 (1.16-3.96)	0.01	1.21 (1.10-1.34)
Cases diagnosed ≥7 years after whole blood collection							
n (cases/controls)	15/118	20/130	17/142	18/133	15/133		85/656
Crude	1.00 (ref)	1.20 (0.58-2.48)	1.06 (0.51-2.21)	1.36 (0.67-2.78)	1.13 (0.53-2.40)	0.06	1.03 (0.92-1.16)
Adjusted [§]	1.00 (ref)	1.27 (0.61-2.63)	1.08 (0.52-2.27)	1.37 (0.67-2.81)	1.14 (0.53-2.45)	0.67	1.05 (0.93-1.18)

[†] Test for trend calculated using the median value for each mtDNA copy number quintile

[‡] Continuous variables are presented based on a 21 unit change, which corresponds to the average unit change within quintiles 2-4.

[§] Adjusted for age, smoking duration, smoking intensity, diabetes